The streak is alive: management narrates back-to-back quarters of the same improvement and shows this quarter extended i
The model's full reasoning — Q1 2023 call → NOWe need to determine if management presents the just-reported period as the latest step in an unbroken, still-running sequence of quarter-after-quarter improvement in the same part of the business, explicitly connecting this period to the immediately preceding period or periods as one continuing climb, with real current-period evidence. We need to check the transcript for any such framing. The call is about Q1 2023 results. Management discusses various operations. They mention that Q1 is typically their softest quarter, and they are on track for full year guidance with a stronger second half. They talk about Rochester expansion, Kensington, etc. They do not seem to present any specific metric as having improved consecutively over multiple quarters. They mention "strong start to the year" at some operations, but that's not a sequential improvement chain. They mention "better-than-anticipated production" at Rochester, but that's not a streak. They mention "results were slightly ahead of expectations" overall. No mention of "another quarter of growth" or "fourth consecutive quarter" etc. They talk about exploration adding reserves over past 5 years, but that's not a quarterly streak. They talk about cost reductions at Palmarejo, but that's not a sequential improvement claim. They mention "easing diesel prices" as a driver, which is external. They also mention one-time payments. No explicit quarter-to-quarter chaining. Thus, answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| CRGO | Freightos Limited | Q1 2024 | 2024-05-20 | C+ |
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| MNKD | MannKind Corporation | Q4 2023 | 2024-02-27 | C |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| MFC | Manulife Financial Corporation | Q3 2023 | 2023-11-09 | C+ |
| BMBL | Bumble Inc. | Q3 2023 | 2023-11-07 | F |
| GOLD | Barrick Gold Corporation | Q3 2023 | 2023-11-02 | C |
| ALL | The Allstate Corporation | Q3 2023 | 2023-11-02 | C+ |
| GRBK | Green Brick Partners, Inc. | Q3 2023 | 2023-11-01 | B |
| TEL | TE Connectivity Ltd. | Q4 2023 | 2023-11-01 | B |
| PTN | Palatin Technologies, Inc. | Q4 2023 | 2023-09-29 | D |
| AEIS | Advanced Energy Industries, Inc. | Q2 2023 | 2023-08-03 | B |
| PFIE | Profire Energy, Inc. | Q1 2023 | 2023-05-13 | B |
| SPIR | Spire Global, Inc. | Q1 2023 | 2023-05-10 | B |
| TSN | Tyson Foods, Inc. | Q2 2023 | 2023-05-08 | D |
| CALX | Calix, Inc. | Q1 2023 | 2023-04-20 | C+ |
| TGT | Target Corporation | Q4 2022 | 2023-02-28 | C |
| VRE | Veris Residential, Inc. | Q4 2022 | 2023-02-22 | D |
| TOST | Toast, Inc. | Q4 2022 | 2023-02-16 | C+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| PKOH | Park-Ohio Holdings Corp. | Q3 2022 | 2022-11-13 | B |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| KFY | Korn Ferry | Q4 2022 | 2022-06-22 | B |
| WRB | W. R. Berkley Corporation | Q1 2022 | 2022-04-26 | B |
| HROW | Harrow Health, Inc. | Q4 2021 | 2022-03-10 | C |
| ALHC | Alignment Healthcare, Inc. | Q3 2021 | 2021-11-06 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| PRPO | Precipio, Inc. | Q3 2018 | 2018-11-19 | D |
| ALB | Albemarle Corporation | Q3 2018 | 2018-11-08 | B |
| FMS | Fresenius Medical Care AG & Co. KGaA | Q2 2018 | 2018-07-31 | C |
| ORAN | Orange SA | Q2 2018 | 2018-07-26 | B |
| NOVT | Novanta Inc. | Q4 2017 | 2018-05-12 | B+ |
| EPC | Edgewell Personal Care Company | Q3 2017 | 2017-08-08 | D |
| CNS | Cohen & Steers, Inc. | Q2 2017 | 2017-07-20 | B |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| GES | Guess?, Inc. | Q1 2017 | 2016-05-25 | F |
| SAN | Banco Santander, S.A. | Q4 2015 | 2016-01-27 | B |
MNKD · Q4 2023 → YESThe question is: Does management present the just-reported period as THE LATEST STEP IN AN UNBROKEN, STILL-RUNNING SEQUENCE OF QUARTER-AFTER-QUARTER IMPROVEMENT IN THE SAME PART OF THE BUSINESS — expl...YES The transcript explicitly frames the just-reported quarter as the second consecutive (or second successive) profitable quarter for the endocrine business unit and for the Company overall. Management ties this directly to actual results in the current period (net income of $1 million GAAP and $7 million non-GAAP in Q4) following the prior 2023 quarter, and states they will continue to focus on growing the profitability of the endocrine business unit, which has had a positive contribution for two straight quarters.
CYBR · Q3 2021 → YESThe question is: Does management present the just-reported period as THE LATEST STEP IN AN UNBROKEN, STILL-RUNNING SEQUENCE OF QUARTER-AFTER-QUARTER IMPROVEMENT IN THE SAME PART OF THE BUSINESS — expl...YES Udi Mokady explicitly frames Q3 as “another amazing quarter” that follows “an incredible second quarter,” using the single word “acceleration” to describe the quarter. He then quantifies the extension with concrete current-period metrics: subscription ARR growth accelerated to 131 % (reaching $139 million), total 38 % ARR growth (reaching $344 million), recurring revenue growth accelerated to 41 % ($89 million), and new logos accelerated to over 230.
MFC · Q3 2023 → YESThe question is: Does management present the just-reported period as THE LATEST STEP IN AN UNBROKEN, STILL-RUNNING SEQUENCE OF QUARTER-AFTER-QUARTER IMPROVEMENT IN THE SAME PART OF THE BUSINESS — expl...YES Roy Gori explicitly frames core ROE as having been ahead of the 15%+ medium-term target for the second consecutive quarter, while noting a 35% rise in core EPS this quarter (on top of steady year-on-year growth in core earnings over the past three quarters). Colin reinforces the sequential nature by stating that core ROE “increase[d] to 16.8%” this quarter.